SCHEMBL5140735

SCHEMBL5140735

COCCNC(=O)c1ccc(Oc2ncnc(OC3CCNCC3)c2C)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.44
MAPK14 Q16539 1/20 0.44
MET P08581 1/20 0.44
KDR P35968 1/20 0.44
GPR119 Q8TDV5 2/20 0.44
PDE4A P27815 2/20 0.43
PDE4B Q07343 2/20 0.43
PDE4C Q08493 2/20 0.43
PDE4D Q08499 2/20 0.43
IP6K1 Q92551 3/20 0.42
SCN9A Q15858 2/20 0.41
TP53 P04637 1/20 0.41
MKNK1 Q9BUB5 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
UTS2R Q9UKP6 1/20 0.39
ROCK2 O75116 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP1A2 P05177 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27755367 0.87 GPR119 (0.51) CYP2C9MAPK14METKDRGPR119
SCHEMBL389132 0.84 GPR119 (0.66) CYP2C9GPR119
SCHEMBL3169529 0.82 GPR119 (0.52) CYP2C9MAPK14METKDRGPR119
SCHEMBL5140736 0.81 GPR119 (0.44) CYP2C9GPR119ABL1
SCHEMBL390219 0.79 GPR119 (0.66) CYP2C9GPR119
Pyridine SCHEMBL27769077 0.78 GPR119 (0.44) CYP2C9GPR119MKNK1MKNK2
SCHEMBL27747805 0.77 GPR119 (0.49) CYP2C9METKDRGPR119
SCHEMBL1897239 0.76 GPR119 (0.67) CYP2C9GPR119
SCHEMBL6066167 0.76 GPR119 (0.46) CYP2C9KDRGPR119
SCHEMBL1890890 0.75 GPR119 (0.66) CYP2C9GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004157-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO Arena Pharmaceuticals, Inc. (US) 2008-12-24 EP disclosed
WO-2007120702-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO ARENA PHARMACEUTICALS, INC. (US) 2007-10-25 WO disclosed